Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interleukin-2 in Idiopathic Membranous Nephropathy
ChiCTR-IPR-17011386Phase 4Recruiting
- Sponsor
- Shijiazhuang Kidney Disease Hospital
- Start
- Jun 2017
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of aldesleukin in idiopathic membranous glomerulonephritis (IMG) (2 arms), sponsored by Shijiazhuang Kidney Disease Hospital. Primary endpoint: 24-hour urinary protein quantity. Started Jun 2017; status: recruiting.
02
Drugs
aldesleukin
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on ChiCTR-IPR-17011386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011386.